Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth To Bolster Drug Development In Japan, Eliminate Drug Lag (Japan)

This article was originally published in PharmAsia News

Executive Summary

Wyeth is taking steps to strengthen its drug-development activities in Japan in order to eliminate the problem of "drug lag" by conducting clinical trials simultaneously in Japan, Europe, and the U.S. Wyeth would then be able to release drugs earlier in Japan, enabling it to better generate maximum revenues before patents expire. The pharmaceutical firm currently has five drugs under review in Japan including 16 compounds in Phase I trials, which entered into Phase I trials in Japan an average of only 26 days after trials began in Europe and North America. This marks a dramatic increase from earlier efforts such as the successor to Prevnar, the company's vaccine against the bacteria that cause pneumococcal disease, which only recently moved into Phase II trials in Japan despite already advancing to Phase III trials in the West. The drug is not expected to debut in Japan until around 2013-2014, compared to around 2010 in the West. (Click here for more - May Require Paid Subscription

You may also be interested in...

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Adolescents In COVID-19 Vaccine Trials: As Pfizer Starts Dosing, US FDA Encouraging Other Sponsors

But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts